Dex treatment, a potent suppressor of systemic inflammation including IL-6, has been shown to reduce mortality in hospitalized COVID-19 patients under oxygen supplementation treatment or mechanical ventilation [34,35]. This evidence concerns the gene IL6 and COVID-19.